Rogaratinib
- Generic Name
- Rogaratinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C23H26N6O3S
- CAS Number
- 1443530-05-9
- Unique Ingredient Identifier
- 98BSN6N516
- Background
Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
Phase 2
Active, not recruiting
- Conditions
- Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8Locally Advanced Gastrointestinal Stromal TumorLocally Advanced SarcomaMetastatic Gastrointestinal Stromal TumorMetastatic SarcomaStage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT04595747
- Locations
- 🇺🇸
UM Sylvester Comprehensive Cancer Center at Plantation, Plantation, Florida, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2019-12-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Registration Number
- NCT04040725
Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-11-09
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 15
- Registration Number
- NCT03762122
- Locations
- 🇨ðŸ‡
Universitaetsspital Basel, Basel, Switzerland
🇨ðŸ‡IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland
🇨ðŸ‡Kantonsspital Baselland Bruderholz, Bruderholz, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath